Accelerate Diagnostics, Inc.
AXDXNASDAQHealthcare
$0.03
+$0.00(+0.00%)
Market Cap$859918
P/E Ratio—
52W High$2.09
52W Low$0.01
Accelerate Diagnostics, Inc. (AXDX) · Cash Flow
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · AXDX · as of 2026-06-10
Financial statements
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2024-12 | 2023-12 | 2022-12 | 2021-12 | 2020-12 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | ($50.05M) | ($61.62M) | ($62.49M) | ($77.70M) | ($78.21M) |
| Depreciation & Amort. | $3.42M | $3.25M | $3.00M | $2.52M | $3.00M |
| Stock-Based Comp. | $4.38M | $5.39M | $10.63M | $22.05M | $16.46M |
| Change in Working Capital | $2.59M | $4.93M | $2.25M | ($0.10M) | ($3.35M) |
| Net Cash from Operations | ($24.19M) | ($40.20M) | ($48.73M) | ($47.32M) | ($50.39M) |
| Investing Activities | |||||
| Capital Expenditure | ($0.51M) | ($1.03M) | ($0.55M) | ($0.60M) | ($1.36M) |
| Purchases of Investments | $0.00M | $0.00M | ($27.51M) | ($30.08M) | ($46.93M) |
| Sales of Investments | $0.00M | $9.70M | $40.48M | $38.99M | $61.90M |
| Net Cash from Investing | ($0.51M) | $8.66M | $12.42M | $8.30M | $13.61M |
| Financing Activities | |||||
| Common Stock Repurchased | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Dividends Paid | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Debt Issued / Repaid | ($1.45M) | $8.75M | ($1.28M) | ($0.36M) | $5.21M |
| Net Cash from Financing | $27.05M | $9.02M | $31.63M | $43.23M | $11.63M |
| Free Cash Flow | |||||
| Free Cash Flow | ($24.70M) | ($41.23M) | ($49.28M) | ($47.93M) | ($51.76M) |
| FCF Margin %(computed) | -211.17% | -341.91% | -386.46% | -406.77% | -463.56% |
Data source: Financial Modeling Prep · Last updated: 2026-06-10 · USD · M
Explore more Accelerate Diagnostics, Inc. data
About Accelerate Diagnostics, Inc. (AXDX) Cash Flow Statement
Accelerate Diagnostics, Inc. generated operating cash flow of ($0.02B) and free cash flow of ($0.02B) for 2024 — a FCF margin of -211.17%. Capital expenditure was ($0.00B).
Frequently asked questions
AXDX · 4 questionsAccelerate Diagnostics, Inc. generated free cash flow of ($0.02B) for 2024, up 40.1% year-over-year.
AXDX free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10